Articles written by Vandana Singh - Benzinga

What's Going On With Cancer Diagnostic Firm Guardant Health On Friday?

Guardant Health beat Q4 estimates with a smaller EPS loss and strong revenue growth. Analysts raised price targets, citing momentum and solid financials.

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?

Exelixis reaffirmed its 2025 sales guidance of $2.15-$2.25 billion and reported sustained long-term efficacy for Cabometyx in advanced renal cell carcinoma.

Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst

Insulet's Q4 sales grew 17.2% to $597.5 million, exceeding forecasts. Omnipod revenue surged, and 2025 guidance projects up to 20% growth.

FDA Approves Mirum Pharmaceuticals' Drug As First For Genetic Disorder With Inability To Break-Down Cholesterol

Mirum Pharmaceuticals' Ctexli wins FDA approval for CTX, a rare lipid storage disease. The company projects 2025 global sales of $420–$435 million.

Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes

Pfizer has discontinued Beqvez for hemophilia B due to low patient demand and will focus on alternative treatments, including its approved therapy, Hympavzi.

Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition

Glaukos reported Q4 sales of $105.5 million, surpassing estimates, while EPS missed. Analysts see strong growth potential as the company expands its business model.

DOJ Investigates UnitedHealth, Probe Accuses Of Inflating Medicare Diagnoses

The Justice Department is investigating UnitedHealth's Medicare billing practices, focusing on diagnoses that led to higher federal payments. The probe follows reports that the company received billions for questionable diagnoses in its Medicare Advantage plans.

Telomir Pharmaceuticals Seeks To Tap Multi-Billion-Dollar Market With Breakthrough In Silver Ion Stabilization For Antibacterial Treatment, Tissue Regeneration

Telomir Pharmaceuticals' Telomir-1 stabilizes Silver(II) for medical use, addressing instability issues in antimicrobial treatments and wound care solutions.

European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat

Indivior's 2025 outlook missed estimates, citing Suboxone sales erosion. The company plans $100 million in cost cuts, with $50M reinvested in Sublocade.

Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook

Repligen reported Q4 EPS of $0.44, beating estimates, with revenue of $167.55 million. The company projects 2025 sales of up to $710 million as the market recovers.

Why Is Penny Stock Aptose Biosciences Trading Higher On Thursday?

Aptose Biosciences advances its Phase 1/2 TUSCANY trial, escalating tuspetinib dosing after a favorable safety review. Enrollment continues across U.S. sites.

Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million

FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its CD46-targeting ADC and PET imaging agent.

Pediatrix Q4 Beats Estimates As Operational Improvements Drive Performance

Pediatrix Medical reported Q4 revenue of $502.36 million, surpassing estimates, with adjusted EPS of $0.51. The company projects 2025 adjusted EBITDA of $215 million–$235 million.

Baxter Q4 Earnings Beat Expectations, Issues Strong 2025 Outlook

Baxter International exceeded Q4 earnings and revenue estimates, with strong pharmaceutical sales. The company issued a mixed 2025 outlook amid cost pressures.

Why Is BioMarin Stock Trading Higher On Thursday?

BioMarin exceeded Q4 earnings expectations, raised 2025 guidance, and projected strong Voxzogo growth. Analysts increased price targets following the results.

Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance

Charles River's Q4 revenue topped estimates despite a 1.1% decline. The company forecasts a revenue drop in 2025, with biotech demand expected to stabilize.

Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer

Bristol Myers' Opdivo improved overall survival in resectable NSCLC, per final Phase 3 data. The study confirms its benefit when combined with chemotherapy.

Stroke Device Maker Penumbra Stock Surges On Earnings Beat, Analysts Boost Price Forecasts After Upbeat 2025 Outlook

Penumbra stock climbs after Q4 earnings surpass expectations, with sales up 10.8% Y/Y. Analysts raise price targets as the company projects strong 2025 growth.

UnitedHealthcare Offers Voluntary Buyouts, Possible Layoffs If Targets Not Met: CNBC

UnitedHealthcare is offering voluntary buyouts to employees, with layoffs possible if targets aren't met. Severance depends on tenure, with final exits by November.

Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate

Precision BioSciences reports early PBGENE-HBV trial data showing safety and antiviral activity in chronic Hepatitis B patients, with more results expected in 2025.